These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28860784)

  • 1. Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial.
    Han N; Hong SH; Kim YS; Kim DK; Kim IW; Ji E; Oh JM
    Ther Clin Risk Manag; 2017; 13():999-1007. PubMed ID: 28860784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
    Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
    Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease-Bone Mineral Density Disorder.
    Hussain I; Tandi R; Singh G; Kaur G; Abhishek ; Dodda S; Patel D; Natarajan B; Maram T; Kedia A; Vempati R; Sahu S; Choubey U
    Cureus; 2023 Jan; 15(1):e33879. PubMed ID: 36812096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
    Ito E; Inaguma D; Koide S; Takahashi K; Hayashi H; Hasegawa M; Yuzawa Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1309-1314. PubMed ID: 29748907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and type II sodium-dependent phosphate cotransporters.
    Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
    Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
    Petkovich M; Melnick J; White J; Tabash S; Strugnell S; Bishop CW
    J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
    Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
    Saji F; Shigematsu T; Sakaguchi T; Ohya M; Orita H; Maeda Y; Ooura M; Mima T; Negi S
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1212-7. PubMed ID: 20739393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
    Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
    Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of calcium with or without calcitriol supplementation on renal function in patients with hypovitaminosis d and chronic kidney disease.
    Mustafar R; Mohd R; Ahmad Miswan N; Cader R; Gafor HA; Mohamad M; Shah SA; Kamaruddin NA; Chiew Tong NK
    Nephrourol Mon; 2014 Jan; 6(1):e13381. PubMed ID: 24719814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
    Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
    Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of calcitriol in treating glucocorticoidinduced osteoporosis in patients with nephrotic syndrome: an open-label, randomized controlled study.
    Chen Y; Wan JX; Jiang DW; Fu BB; Cui J; Li GF; Chen CM
    Clin Nephrol; 2015 Nov; 84(5):262-9. PubMed ID: 26396095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.